Publications by authors named "Els Vercammen"

Claim this Profile
R
Reply to T. Hasegawa et al and I. Gross et al.
Brian Leyland-Jones, Els Vercammen, Liang Xiu

J Clin Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
Brian Leyland-Jones, Igor Bondarenko, Gia Nemsadze, Vitaliy Smirnov, Iryna Litvin, Els Vercammen

J Clin Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
Iain C Macdougall, Nicole Casadevall, Francesco Locatelli, Christian Combe, Gerard M London, Els Vercammen

Nephrol Dial Transplant· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.
Bonnie Fijal, Deborah Ricci, Els Vercammen, Peter A Palmer, Fotis Fotiou

Pharmacogenomics· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Jean-Louis Vincent, Herbert D M H Spapen, Jacques Creteur, Michael Piagnerelli, Ives Hubloue, Els Vercammen

Crit Care Med· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
Brian Leyland-Jones, Vladimir Semiglazov, Marek Pawlicki, Tadeusz Pienkowski, Sergei Tjulandin, Els Vercammen

J Clin Oncol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of erythropoietin in critically ill subjects.
Abhijit Chakraborty, Jaya Natarajan, Mary Guilfoyle, Nancy Morgan, Els Vercammen

J Clin Pharmacol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
Emilio Bajetta, Els Vercammen, Uwe Reinhardt, Riaz Janmohamed, Ricardo Marques da Costa

Tumori· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Timothy J Littlewood, Johan Nortier, Bernardo Rapoport, Marek Pawlicki, Gilbert de Wasch, Els Vercammen

Hematol Oncol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis